Skip to main content

Advertisement

Table 1 Baseline characteristics of the study subjects

From: Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study

Characteristics Healthy adults
(N = 1200)
Patients with underlying illnesses
(N = 300)
Patients with malignancy
(N = 49)
Patients with diabetes mellitus
(N = 180)
Patients with autoimmune diseases
(N = 10)
Patients with chronic renal diseases
(N = 61)
Sex Male 607 (51%) 188 (63%)* 26 (53%) 120 (67%)* 2 (20%)** 40 (66%)*
Age (y) Mean ± SD 62.0 ± 8.0 66.0 ± 8.0 71.0 ± 9.0* 65.0 ± 8.0* 61.0 ± 7.0 69.0 ± 8.0*
50–59 530 (44%) 63 (21%)* 3 (6%)* 46 (26%)* 4 (40%) 10 (16%)*
60–69 425 (35%) 129 (43%) 21 (43%) 80 (44%) 4 (40%) 24 (39%)
70+ 245 (20%) 108 (36%) 25 (51%) 54 (30%) 2 (20%) 27 (44%)
History of HZ Present 155 (13%) 49 (16%) 11 (22%)** 28 (16%) 1 (10%) 9 (15%)
Previous vaccination Present 3 (0.3%) 3 (1%)** 2 (4%)* 1 (1%) 0 (0%) 0 (0%)
White blood cells (/μL) Mean ± SD 6289 ± 1685 5386 ± 1223 6505 ± 1811 6100 ± 520 5980 ± 1430
HbA1c (%) Mean ± SD 7.0 ± 1.0
Duration of diabetes mellitus (y) Mean ± SD 8.0 ± 7.0
Creatinine (mg/dL) Mean ± SD 0.99 ± 0.15
eGFR (mL/min/1.73 m2) Mean ± SD 53 ± 4
Dialysis Present 0 (0%)
  1. Data are expressed as n (%) unless otherwise indicated
  2. HZ Herpes zoster, SD Standard deviation
  3. *P < 0.05, **P < 0.1 (compared with the proportion of subjects among healthy adults)